VIDEO: ‘Intriguing’ psoriatic arthritis treatments in the pipeline

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

There are a few intriguing things coming up in the pipeline. Unfortunately, to my knowledge, there are no major new mechanisms that are coming about, but there are some expansions on our existing mechanisms which are somewhat exciting. So the first is izokibep (Acelyrin), which is an IL-17 inhibitor. It is a small molecule drug and this has had abstracts both at ACR and at UR. The ostensible appeal of izokibep is that is a smaller molecule construct than the immunoglobulins we usually use, but it may have better penetration into the diseased organ and so there's some thought whether perhaps these might be a little bit more effective for enthesitis than seen with the other IL-17 inhibitors. This is, to my mind, yet to be conclusively demonstrated, but I think it's an intriguing molecule and something I'll be keeping an eye on.

We also have, as I mentioned, deucravacitinib, which is a TYK2 inhibitor, and we're waiting on further data on this. Along with that, we have zasocitinib (Takeda), which is another TYK2 inhibitor, which had promising looking data at UR over this past year and the last one, which we're still waiting on approval for, but is bimekizumab. Bimekizumab, as I mentioned, currently has FDA approval for psoriasis, but we are hoping to see that become available for psoriatic arthritis and axial spondyloarthritis, as well.